We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02410551
Previous Study | Return to List | Next Study

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02410551
First Posted: April 7, 2015
Last Update Posted: January 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
CTI BioPharma
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
April 2, 2015
April 7, 2015
January 25, 2017
June 15, 2015
January 20, 2017   (Final data collection date for primary outcome measure)
Progression-free Survival (PFS) [ Time Frame: 1 year ]
Progression-free survival defined as the time of stem-cell transplant to the time of death or disease progression.
Same as current
Complete list of historical versions of study NCT02410551 on ClinicalTrials.gov Archive Site
  • Neutrophil Engraftment [ Time Frame: 3 weeks after transplant ]
    Neutrophil engraftment defined as a sustained ANC > 0.5 x 109/L for 3 consecutive days and evidence of donor chimerism by D+28.
  • Platelet Engraftment [ Time Frame: 1 month ]
    Platelet engraftment defined as a sustained first of three consecutive laboratory values of platelet ³ 20x109/L with no platelet transfusions administered for 7 consecutive days.
Same as current
Not Provided
Not Provided
 
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN)
The goal of this clinical research study is to learn if giving pacritinib before standard of care drugs followed by an allogeneic stem cell transplant can help to control myeloproliferative neoplasms. The safety of this therapy will also be studied.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will take pacritinib at about the same time each day by mouth, 2 times each day. Your doctor will tell you when to start and stop taking pacritinib. You may be able to take the drug for about 2-6 months depending on how you tolerate the drug and when your transplant date is. If you do not receive your transplant, you may be able to continue taking the study drug as long as the doctor thinks it is in your best interest.

You must swallow the capsules whole with a glass (about 8 ounces) of water. Do not open, break, or chew the capsules.

If you vomit or miss a dose of pacritinib, take your next dose of pacritinib at your regular time. Do not "make up" a missed or vomited dose.

You will be given a study drug diary to write down what time you take each dose of pacritinib. You need to bring the study drug diary, any leftover study drug, and any empty study drug containers with you to each study visit.

The dose of pacritinib you receive may be lowered or stopped, if the doctor thinks it is needed.

About 21 days after your last dose of pacritinib, you will given standard of care drugs and you will have an allogeneic stem cell transplant. Your doctor will explain this treatment and the stem cell transplant to you in more detail. You will be required to sign a separate consent form.

Study Visits:

One (1) time each month:

  • You will have a physical exam.
  • Blood (about 2 teaspoons) will be drawn for routine tests and to check your kidney and liver function.
  • You will have an electrocardiogram (EKG -- a test that measures the electrical activity of the heart).

On Day 14 (+/- 2 days) of of Cycle 1, blood (about 2 teaspoons) will be drawn for routine tests and to check your kidney and liver function. You can have this blood drawn at a local lab or clinic that is closer to your home. The results will be sent to the study doctor at MD Anderson.

During Week 2 of Cycle 1, a member of the study staff will call to ask you about any symptoms you may be having. This call should last about 5-10 minutes.

Length of Study:

You will be on study for up to 1 year after the transplant. You may be taken off study early if the disease gets worse, if you have any intolerable side effects, of if you are unable to follow study directions.

Your participation on this study will be over after about 1 year of follow-up tests.

End-of-Study Visit:

Within about 7 days after your last dose of pacritinib, but before your stem cell transplant:

  • You will have a physical exam and an ultrasound, MRI, or CT scan of your abdomen to measure your liver and spleen.
  • You will have an EKG.

Before your transplant, you will have a bone marrow biopsy/aspiration to check the status of the disease.

Follow-Up Tests:

You will have follow-up visits at about 1, 3, 6, and 12 months after the transplant:

  • You will complete 3 questionnaires about your symptoms and quality of life. It should take about 20-30 minutes to complete the questionnaires.
  • At Month 3, you will have a physical exam and an ultrasound, MRI, or CT scan of your abdomen to measure your liver and spleen. This will be repeated at Month 12, if your doctor thinks it is needed.
  • At Months 3 and 12, you will have a bone marrow biopsy/aspiration to check the status of the disease.

This is an investigational study. Pacritinib is not FDA approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the study drug is designed to work.

Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Myeloproliferative Diseases
  • Drug: Pacritinib
    200 mg by mouth twice a day for 60 days.
  • Drug: Busulfan
    Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
    Other Names:
    • Busulfex
    • Myleran
  • Behavioral: Questionnaires
    Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
    Other Name: Surveys
  • Behavioral: Phone Calls
    Phone calls made by study staff to participant on second and third week of each month.
  • Procedure: Allogeneic Stem Cell Transplantation
    Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
    Other Name: Stem cell transplant
  • Drug: Fludarabine
    Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
    Other Names:
    • Fludarabine phosphate
    • Fludara
Experimental: Pacritinib + Allogeneic Stem Cell Transplantation
Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
Interventions:
  • Drug: Pacritinib
  • Drug: Busulfan
  • Behavioral: Questionnaires
  • Behavioral: Phone Calls
  • Procedure: Allogeneic Stem Cell Transplantation
  • Drug: Fludarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
4
January 20, 2017
January 20, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with Idiopathic Myelofibrosis or Myelofibrosis secondary to Polycythemia Vera or Essential Thrombocythemia.
  2. Patients 18 years to less than or equal to 70 years.
  3. Patients wanting to pursue transplant.
  4. Patients must have a Zubrod PS equal or less than 2.
  5. Calculated creatinine clearance greater than 50ml/min. using the Cockcroft-Gault equation.
  6. Ejection fraction equal or above 40%.
  7. Serum direct bilirubin less than 1 mg/dl (unless due to Gilbert's syndrome or hemolysis).
  8. SGPT equal or less than 4 x normal values.
  9. Corrected DLCO equal or above 50% of expected.
  10. Negative Beta HCG test in a woman with childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) and if fertile, males and females must agree to use contraceptives.

Exclusion Criteria:

  1. Patients with low risk myelofibrosis.
  2. Uncontrolled life-threatening infections.
  3. HIV positive.
  4. Patients with active viral hepatitis.
  5. Prior treatment with Pacritinib.
  6. Prior stem cell transplant.
  7. QTc greater than 450 ms.
  8. CYP3A4 strong or moderate inhibitors/inducers in the past 7 days.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02410551
2014-0786
NCI-2015-01123 ( Registry Identifier: NCI CTRP )
No
Not Provided
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
CTI BioPharma
Principal Investigator: Uday Popat, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP